-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
5th AACR-IASLC International Joint Conference: Translational Progress through Basic Research
By Monte M. Winslow, PhD Posted: February 2018 Over 4 rainy days in San Diego, California, more than 220 participants from 15 different countries heard presentations that spanned a very wide range of basic, translational, and clinical lung cancer research. This joint conference between the IASLC and the American Association for Cancer Research (AACR) was…
-
European Union Position Statement on Lung Cancer CT Screening: The Next 18 Months
By John K. Field, PhD, and Matthijs Oudkerk, MD, PhD Lung cancer kills more Europeans than any other cancer. In 2014, 272,000 citizens of the twenty-eight countries in the European Union (EU) died from lung cancer, which is 20.1% of all cancer deaths.1 When implemented in the general population, lung cancer screening using CT saves…
-
Writing for Publication: Expanding the Voices of Nursing in Thoracic Oncology
By Kathleen A. Gamblin, RN, BSN, OCN Posted: December 2017 The nursing perspective and the views of other ancillary specialties are frequently missing in the thoracic oncology literature. This deficiency needs to be addressed; the current model of healthcare delivery in the US and around the world includes an ever-expanding role for nurses, nurse practitioners,…
-
Advocating for Inclusion of the Patient’s Voice
By Lori L. Alexander, MTPW, ELS, MWC Posted: December 2017 Since 2006, the Bonnie J. Addario Lung Cancer Foundation (ALCF) has brought together a diverse group of physicians, organizations, industry partners, and individuals, along with patients, survivors, and their families, to identify solutions and to make timely and meaningful changes in the research and management…
-
Discussing ALCHEMIST with Dr. Shakun Malik
Posted: December 2017 Patients with completely resected early-stage non-small cell lung cancer (NSCLC) have approximately a 50% chance of experiencing disease recurrence following standard treatment. In 2014, the NCI initiated a group of randomized clinical trials, called the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), to test adjuvant treatments to prevent cancer…
-
IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology
By Jyoti Patel, MD, and Heather A. Wakelee, MD Posted: December 2017 The IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology was held September 14-16, 2017 and brought together nearly 400 participants to discuss important topics in lung cancer prevention, detection, and care. The multidisciplinary nature of the meeting was most apparent in the initial…
-
INFORMED: An Interview with Sean Khozin, MD, MPH
Posted: December 2017 The Information Exchange and Data Transformation (INFORMED) initiative was launched by the U.S. Food and Drug Administration (FDA) and the Innovation, Design, Entrepreneurship and Action (IDEA) Lab of the U.S. Department of Health and Human Services. INFORMED is intended to promote the use of big data analytics to analyze the large and…
-
Q & A with Yi-Long Wu, MD
What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?Posted: October 2017 Current Chinese Lung Cancer Diagnosis and Treatment Guideline from the Chinese Society of Clinical Oncology (CSCO) recommends adjuvant platinum- based doublet chemotherapy as the standard of care (SOC) for completely resected stage II-III…
-
Proton-Beam Therapy Versus Photon-Beam Therapy: The Debate Continues
By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 For patients who present with inoperable, locally advanced lung cancer, photon-based chemoradiation remains the standard of care. Despite advanced radiation-delivery techniques, such as multi-leaf collimators, intensity-modulated radiotherapy (IMRT), and imageguided radiotherapy (IGRT), radiation oncologists continue to explore ways to extend the ALARA principle, that is, the…
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis has led to the routine use of targeted therapy in metastatic lung cancer but, to date, the use of these agents in the adjuvant setting…
View ILCN Archives
Provider Resources
Popular Articles